Hi, what are you looking for?
Jewish Business News
Search results for "Clal Biotechnology "
Business
Israel’s Clal Biotechnology Industries has sold the exclusive worldwide commercialization rights for its cancer treatment pidilizumab to the American company Medivation. The rights are...
Business
– Clal Biotechnology and Hyperion have agreed on an independent assessment of Andromeda’s Type 1 diabetes treatment. – Clal Biotechnology (TASE: CBI), managed...
Court
Clal Biotechnology Industries Ltd. (TASE: CBI announced yesterday that it had filed a $200 million suit against drug company Hyperion Therapeutics Inc. (Nasdaq: HPTX)...
World News
Clal Biotechnology Industries Ltd. (TASE: CBI) notified the Tel Aviv Stock Exchange this morning that it had contacted Hyperion Therapeutics Inc. (Nasdaq: HPTX) as...
Business
– Clal Biotechnology Industries Ltd. (TASE: CBI) has signed a non-binding letter of intent to sell diabetes treatment developer Andromeda Biotech Ltd. to a US pharmaceutical company for...
Business
– Blavatnik’s Access Industries, which owns 49.9% of Clal Industries, will buy the public’s holdings under an offer to purchase. – – / By...
Money
– Access Industries has made an offer to purchase for Clal Industries at a 24% premium on today’s opening price. – Len Blavatnik /...
Business
Gamida Cell develops cellular and immune therapies for the treatment of cancer and orphan genetic diseases.
Business
Clal Biotechnology Industries Ltd. reported to the Tel Aviv Stock Exchange Today that its wound and burn care solutions unit MediWound Ltd. has been awarded...
World News
Israel’s biomedical firm D-Pharm Ltd announced the successful completion of fundraising via a public rights issue, of 12.8 million NIS ($3.2 million) in aggregate....